![]() NanoString NS Wind Down (formerly NanoString Technologies) is a provider of life science tools for translational research and molecular diagnostics. | ![]() EKF Diagnostics EKF Diagnostics Holdings is a company that manufactures point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose, and lactate. | ![]() Viapath Viapath provides pathology and testing its partners, and NHS and private sector organizations. | ![]() 10X Genomics 10X Genomics is a company building products for research institutions and pharmaceutical companies across the life sciences, including oncology, immunology, and neuroscience. | |||
Founding Date | Founding Date 2003 | Founding Date 2011 | Founding Date 1990 | Founding Date 2009 | Founding Date 2012 | Founding Date 2017 |
Type | Type Subsidiary | Type Public | Type Public | Type Private | Type Public | Type Public |
Tags | ||||||
Locations | Locations Seattle, US HQ Amsterdam, NL | Locations Fremont, US HQ West Wickham, GB | Locations Penarth, GB HQ Shanghai, CN Barleben, DE Leipzig, DE Boerne, US Elkhart, US | Locations Bedford, GB HQ London, GB London, GB London, GB London, GB Orpington, GB | Locations Pleasanton, US HQ Shanghai, CN Leiden, NL Singapore, SG San Francisco, US | Locations Salt Lake City, US HQ Wuxi, CN Walluf, DE Willich, DE Milano, IT Doetinchem, NL Calamba, PH see more |
Employees | Employees 7038% decrease | Employees 22344% decrease | Employees 303 | Employees 2701% decrease | Employees 1,17810% decrease | Employees 2,4004% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 340.9 m | Valuation ($) 157.5 m | Valuation ($) N/A | Valuation ($) 1.9 b | Valuation ($) 543.9 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) $127.3m (FY, 2022) | Revenue (est.) $69.6m (FY, 2025) | Revenue (est.) £51.6m (FY, 2025) | Revenue (est.) £122m (FY, 2018) | Revenue (est.) $642.8m (FY, 2025) | Revenue (est.) $844.6m (FY, 2025) |
Cost of goods | Cost of goods $65.5m (FY, 2022) | Cost of goods $53.9m (FY, 2025) | Cost of goods £19.7m (FY, 2025) | Cost of goods £88.9m (FY, 2018) | Cost of goods $198.9m (FY, 2025) | Cost of goods $554.1m (FY, 2025) |
Gross profit | Gross profit $61.8m (FY, 2022) | Gross profit $15.8m (FY, 2025) | Gross profit £32.1m (FY, 2025) | Gross profit £33.1m (FY, 2018) | Gross profit $443.9m (FY, 2025) | Gross profit $290.5m (FY, 2025) |
Net income | Net income ($159.5m) (FY, 2022) | Net income ($81.3m) (FY, 2025) | Net income £2.5m (FY, 2025) | Net income £2.5m (FY, 2018) | Net income ($43.5m) (FY, 2025) | Net income ($69.9m) (FY, 2025) |
Operating ⚠ | ||||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications 480 (FY, 2019) | Patent Applications 125 (FY, 2020) |
Patents (US) | Patents (US) 34 (Q2, 2022) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 275 (FY, 2020) |
Patents Issued | Patents Issued N/A | Patents Issued 16 (FY, 2021) | Patents Issued N/A | Patents Issued N/A | Patents Issued 200 (FY, 2019) | Patents Issued N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 152m | Total funding raised $ 75m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 195.5m | Total funding raised N/A |

Personalis is a biotechnology company that specializes in cancer genomics.
View company
EKF Diagnostics Holdings is a company that manufactures point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose, and lactate.
View company
Viapath provides pathology and testing its partners, and NHS and private sector organizations.
View company
10X Genomics is a company building products for research institutions and pharmaceutical companies across the life sciences, including oncology, immunology, and neuroscience.
View company